Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer

Oncology Reports

Volumn 21, Issue 1, 2009, Pages 33-37

  Tanaka, Tomoaki ^a   Kawashima, Hidenori ^a   Matsumura, Kentaro ^a   Yamashita Hosono, Tomoko ^a   Yoshimura, Rikio ^a   Kuratsukuri, Katsuyuki ^a   Harimoto, Koji ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Hormone refractory prostate cancer; Orotate phosphoribosyl transferase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FLUOROURIDINE; MESSENGER RNA; OROTATE PHOSPHORIBOSYLTRANSFERASE; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG METABOLISM; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TISSUE SECTION; BIOSYNTHESIS; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; MICRODISSECTION; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRODISSECTION; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 61449318283     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000186     Document Type: Article

References (26)

1. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
2. Miyake H, Hara I, Yamazaki H and Eto H: Clinical outcome of oral uracil/ tegafur (UFT) therapy for patients with hormone refractory prostate cancer. Oncol Rep 14: 673-676, 2005.
3. Bhandari MS, Pienta KJ, Fardig J, Olson K and Smith DC: Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. Cancer 106: 1715-1721, 2006.
4. Hoshi S, Ohyama C, Hagisawa S, Ono K, Satoh M, Saito S, Fukuzaki A and Arai Y: Complete regression of bone metastases on super bone scan, by low-dose cisplatin, UFT, diethylstilbestrol diphosphate, and dexamethasone in a patient with hormone-refractory prostate cancer. Int J Clin Oncol 8: 118-120, 2003.
5. Kubota T: 5-fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol 8: 127-131, 2003.
6. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T and Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7: 335-342, 2002.
7. Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S and Ueda R: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49: 345-351, 2005.
8. Sakamoto E, Nagase H, Kobunai T, Oie S, Oka T, Fukushima M and Oka T: Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochem Biophys Res Commun 363: 216-222, 2007.
9. Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y and Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119: 783-791, 2006.
10. Fujii R, Seshimo A and Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 8: 72-78, 2003.
11. Katsumata K, Tomioka H, Sumi T, Yamashita S, Takagi M, Kato F, Nakamura R, Koyanagi Y, Aoki T and Kato K: Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens. Cancer Chemother Pharmacol 51: 155-160, 2003.
12. Birtle AJ, Newby JC and Harland SJ: Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer 91: 1472-1476, 2004.
13. Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E and Benoit G: Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 14: 1291-1298, 2003.
14. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI and Danenberg PV: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4: 135-142, 2000.
15. Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res 6: 986-994, 1996.
16. Gibson UE, Heid CA and Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 6: 995-1001, 1996.
17. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakanishi H and Miki T: Significance of orotate phosphoribosyltransferase activity in renal cell carcinoma. J Urol 171(2 Pt 1): 605-610, 2004.
18. Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN and Miki T: Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 100: 723-731, 2004.
19. Miyoshi Y, Uemura H, Ishiguro H, Kitamura H, Nomura N, Danenberg PV and Kubota Y: Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 8: 260-265, 2005.
20. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94: 633-638, 2003.
21. Tokunaga Y, Nakagami M, Tokuka A and Ohsumi K: Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: immunohistochemistry using a new monoclonal antibody. Anticancer Res 23: 1763-1768, 2003.
22. Horiguchi J, Takei H, Koibuchi Y, Iijima K, Ninomiya J, Uchida K, Ochiai R, Yoshida M, Yokoe T, Iino Y and Morishita Y: Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer 86: 222-225, 2002.
23. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003.
24. Oeda M, Yoshida K, Sanada Y, Wada Y, Suzuki T, Mizuiri H, Konishi K, Shigematsu H, Tanabe K and Fukushima M: The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance. Oncol Rep 16: 1165-1172, 2006.
25. Taomoto J, Yoshida K, Wada Y, Tanabe K, Konishi K, Tahara H and Fukushima M: Overexpression of the orotate phosphoribosyltransferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines. Oncology 70: 458-464, 2006.
26. Miyazaki K, Shibahara T, Sato D, Uchida K, Suzuki H, Matsui H, Yanaka A, Nakahara A and Matsuzaki Y: Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol 41: 140-150, 2006.